Verkauf durch Sack Fachmedien

Klote

Adapting to Change

Federal Policy Dynamics and the Pharmaceutical Industry

Medium: Buch
ISBN: 978-1-041-15981-0
Verlag: CRC Press
Erscheinungstermin: 23.10.2025
Lieferfrist: bis zu 10 Tage

The US pharmaceutical landscape is in the midst of impactful shifts. A series of ambitious, aggressive, and often interconnected federal policy changes—from direct drug price controls and sweeping Pharmacy Benefit Manager reforms to strategic initiatives to reshore manufacturing and rapidly evolving FDA approaches—is creating a new reality for industry leaders, innovators, and strategists. In this analysis, a federal policy expert unpacks the complex forces reshaping how life-saving therapies are researched, developed, manufactured, and delivered.

Key Features

•Understand the Interconnectedness of U.S. Federal Policies.

•Analyze the Strategic Impacts of Key Legislation and Executive Actions.

•Evaluate Challenges and Opportunities in a Dynamic Regulatory Environment.

•Analyze the Interplay of U.S. Federal Actions and Industry Operations.

•Formulate Adaptive Strategies for Industry Resilience.


Produkteigenschaften


  • Artikelnummer: 9781041159810
  • Medium: Buch
  • ISBN: 978-1-041-15981-0
  • Verlag: CRC Press
  • Erscheinungstermin: 23.10.2025
  • Sprache(n): Englisch
  • Auflage: 1. Auflage 2025
  • Produktform: Gebunden, HC gerader Rücken kaschiert
  • Gewicht: 300 g
  • Seiten: 124
  • Format (B x H x T): 145 x 222 x 11 mm
  • Ausgabetyp: Kein, Unbekannt
Autoren/Hrsg.

Autoren

Chapter 1: Introduction – Adapting to Change. Chapter 2: Key Forces Impacting Pharma. Chapter 3: Additional Emerging Policy Dynamics. Chapter 4: Small Businesses in the New Pharma Paradigm. Chapter 5: Impact of/on Compounding Pharmacies. Chapter 6: The Most Favored Nation (MFN) Drug Pricing Executive Order. Chapter 7: Medicare Part B vs. Part D Drug Coverage. Chapter 8: International Impacts on Pharma. Chapter 9: Strategic Recommendations for the Pharmaceutical Industry. Chapter 10: Conclusion – Forging the Future – Resilience and Value in Pharma's New Era.